Chuanxiong-Renshen medicine pair ameliorates neuroinflammation in Alzheimer’s disease through modulation of the PKC-α/NF-κB signaling pathway

These findings demonstrate that CRM exerts neuroprotective effects in AD through dual mechanisms: inhibition of PKC-α/NF-κB-mediated neuroinflammation and restoration of gut microbiota homeostasis. Thus, CRM represents a promising multi-target therapeutic strategy for AD.